Physician profile
Jaime Cancel
NPI 1689778706
$17,127.15
in general payments reported to CMS, 2019-2025
45 companies · $3,473 in 2025
The $3,473 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $1,068 · 2021: $2,612 · 2022: $2,877 · 2023: $2,960 · 2024: $3,085 · 2025: $3,473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,439 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,438.67 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,025.04 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $2,868.80 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $1,722.43 | 2020-2025 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,694.40 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $1,055.90 | 2021-2025 | Dupixent |
| Ethicon INC. | $696.96 | 2019-2024 | Monarch Platform |
| Actelion Pharmaceuticals US, INC. | $585.72 | 2019-2023 | Opsumit, Uptravi |
| Genzyme Corporation | $579.83 | 2019-2025 | |
| Grifols USA, LLC | $550.84 | 2019-2025 | Prolastin-C Liquid |
| Paratek Pharmaceuticals, INC. | $488.26 | 2019-2025 | Nuzyra |
| Insmed, INC. | $469.74 | 2019-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $466.91 | 2019-2024 | Yupelri |
| Baxter Healthcare | $328.05 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $293.16 | 2021-2025 | Winrevair |
| United Therapeutics Corporation | $258.67 | 2022-2025 | Tyvaso, Tyvaso |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $224.27 | 2022-2025 | Tezspire |
| Electromed, INC. | $196.60 | 2019-2025 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $167.62 | 2021-2023 | |
| Verona Pharma, INC. | $130.33 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $109.68 | 2020-2021 | |
| Intuitive Surgical, INC. | $100.86 | 2022 | |
| Genentech USA, INC. | $99.58 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $93.40 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $84.78 | 2019-2021 | |
| Abbvie INC. | $81.36 | 2021-2024 | |
| Viatris Specialty LLC | $78.99 | 2025 | Yupelri |
| Allergan, INC. | $78.80 | 2019-2020 | |
| Circassia INC. | $70.66 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $61.99 | 2024 | Purified Cortrophin Gel |
| Inogen, INC. | $58.87 | 2025 | |
| Fisher & Paykel Healthcare INC | $51.29 | 2022 | |
| Pulmonx Corporation | $38.83 | 2022-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Ceribell, INC. | $35.00 | 2024 | Pocket Eeg Device |
| Teva Pharmaceuticals USA, INC. | $34.27 | 2021 | |
| Gilead Sciences, INC. | $32.58 | 2021 | |
| Mallinckrodt Enterprises LLC | $29.87 | 2019 | |
| Nabriva Therapeutics, Plc | $29.81 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $27.63 | 2025 | Acthar |
| Boston Scientific Corporation | $24.10 | 2021 | |
| Vapotherm INC | $24.03 | 2019 | |
| Ambu INC. | $18.89 | 2024 | |
| Tactile Systems Technology INC | $18.62 | 2025 | Flexitouch Plus, Nimbl |
| Optinose US, INC. | $15.01 | 2019 | |
| Breas Medical, INC. | $13.10 | 2022 | |
| Olympus America INC. | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Cancel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.